The Enterprise Value as of June 2026 (TTM) for Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is 430.95M

According to Contineum Therapeutics, Inc. Class A Common Stock’s latest financial reports and current stock price. The company's current Enterprise Value is 430.95M. This represents a change of 51.10% compared to the average of 285.21M of the last 4 quarters.

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Historical Enterprise Value (quarterly & annually)

How has CTNM Enterprise Value performed in the past?

The mean historical Enterprise Value of Contineum Therapeutics, Inc. Class A Common Stock over the last ten years is 390.32M. The current 430.95M Enterprise Value has changed 10.94% with respect to the historical average. Over the past ten years (40 quarters), CTNM's Enterprise Value was at its highest in in the March 2024 quarter at 573.08M. The Enterprise Value was at its lowest in in the June 2023 quarter at 0.

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Contineum Therapeutics, Inc. Class A Common Stock Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Average Enterprise Value

How has CTNM Enterprise Value performed in the past?

The current Enterprise Value of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Enterprise Value vs. Peers

How is CTNM’s Enterprise Value compared to its peers?

Contineum Therapeutics, Inc. Class A Common Stock’s Enterprise Value is greater than Mereo BioPharma Group plc (12.46M), greater than Kyverna Therapeutics, Inc. (329.49M), greater than Lexeo Therapeutics, Inc. Common Stock (278.74M), greater than Silence Therapeutics plc (310.47M), greater than AC Immune S.A. (172.37M), less than Alto Neuroscience, Inc. (495.40M), greater than Aldeyra Therapeutics, Inc. (56.68M), less than Capricor Therapeutics, Inc. (1.10B), greater than Candel Therapeutics, Inc. (276.91M), greater than Amarin Corporation plc (189.73M),

Build a custom stock screener for Contineum Therapeutics, Inc. Class A Common Stock (CTNM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Contineum Therapeutics, Inc. Class A Common Stock using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Contineum Therapeutics, Inc. Class A Common Stock or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.